Brinter raised €1.2M in a seed funding round led by early-stage VC Innovestor.
Brinter, a Turku, Finland-based developer of a 3D bio solution, announced the completion of a €1.2M ($1.5M) seed funding round.
The money was raised from local investors from Finland led by Innovestor.
Brinter, founded as 3DTech in 2019 by CEO Tomi Kalpio, built a bioprinting platform (The Brinter Bioprinter platform) providing access to 3D bioprinting solutions and services for pharmaceutical, biotechnological and cosmetic industries, universities, and research facilities.
The platform can be used in a variety of applications, such as a versatile tool for basic research in tissue engineering and regenerative medicine. 3D bioprinting solutions also offer a cost-effective approach to shorten and enhance the productivity of the drug discovery process.
Customers include Nanoform, VTT, BEST group at the University of Glasgow, Johannes Gutenberg University of Mainz, the University of Oulu, and the University of Helsinki.